Paul R Atkinson

Title: Paul R Atkinson: Innovator in Protein Analog Research

Introduction

Paul R Atkinson is a notable inventor based in Indianapolis, IN (US). He has made significant contributions to the field of protein analogs, holding a total of 4 patents. His work focuses on innovative processes that enhance the preparation of obesity protein analogs, showcasing his expertise in biochemistry and molecular biology.

Latest Patents

Atkinson's latest patents include a "Process for preparing obesity protein analogs." This invention is directed towards an improved method for achieving high yields of obesity protein analogs using a dipeptidylaminopeptidase isolated from the slime mold, Dictyostelium discoideum. Another significant patent is the "Method for removing N-terminal dipeptides from precursor polypeptides." This method involves removing dipeptides from the amino terminus of precursor polypeptides, utilizing an immobilized dipeptidylaminopeptidase from the same slime mold, which has a mass of about 225 kilodaltons and a pH optimum of about 3.5. The precursor polypeptides may be produced recombinantly and can serve as analogs of naturally occurring polypeptides.

Career Highlights

Atkinson is currently associated with Eli Lilly and Company, a leading pharmaceutical firm known for its innovative research and development in healthcare. His work at Eli Lilly has allowed him to contribute to advancements in therapeutic solutions, particularly in the area of obesity treatment.

Collaborations

Some of his notable coworkers include Lisa Kay Foster and Matthew Dale Hilton. Their collaborative efforts have likely contributed to the success of the projects they have undertaken together.

Conclusion

Paul R Atkinson's innovative work in the field of protein analogs has led to significant advancements in biochemistry. His patents reflect a commitment to improving health outcomes through scientific research and innovation.